FDA OKs New Device to Treat BPH

Mark Crane


September 13, 2013

The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with an enlarged prostate.

The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.

"The UroLift provides a less invasive alternative to treating [benign prostatic hyperplasia] than surgery," Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in a release. "This device also may offer relief to men who cannot tolerate available drug therapies."

The FDA's review of the UroLift system included data from 2 clinical studies of 274 men with BPH implanted with 2 or more UroLift sutures. Both studies showed that physicians successfully inserted UroLift in 98% of participants.

The studies also found a 30% increase in urine flow and a steady amount of residual urine in the bladder. Study participants answered validated questionnaires about their BPH-related symptoms and quality of life, reporting a decrease in symptoms and an increase in quality of life in the 2 years after treatment.

Minor adverse events reported included pain or burning during urination, blood in the urine, frequent or urgent need to urinate, incomplete emptying of the bladder, and decreased urine flow. Investigators did not report any serious device-related adverse events.

Severe BPH can lead to serious problems over time, such as strain on the bladder, urinary tract infections, bladder or kidney damage, bladder stones, and the inability to control urine (incontinence). Current treatment options to relieve symptoms associated with BPH include drug therapy or surgical procedures including removal of the enlarged part of the prostate.

The FDA reviewed the UroLift system through its de novo classification process, a regulatory pathway for some novel low-to-moderate risk medical devices that are not substantially equivalent to an already legally marketed device.

The UroLift System is manufactured by NeoTract Inc of Pleasanton, California.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.